Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 21, 2022; 28(23): 2609-2624
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2609
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2609
Table 1 Magnetic resonance imaging sequences and data acquisition parameters
Parameter | Magnetic resonance imaging sequences | |||||||
T2 FSE sagittal | T2 FSE axial | T2 FSE coronal | T1 FSE axial | DWI axial | T1 + GD axial | T1 + GD coronal | T1 + GD coronal | |
Repetition time in ms | 5325 | 9890 | 7509 | 850 | 7750 | 435 | 295 | 265 |
Echo time in ms | 102 | 102 | 102 | Min | Min | Min | Min | Min |
Slices, n | 30 | 40 | 30 | 40 | 40 | 40 | 40 | 30 |
FOV | 24 | 20 | 20 | 20 | 20 | 20 | 20 | 24 |
Slices thickness in mm | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Broadband in Hz/Px | 62.5 | 62.5 | 50 | 62.5 | - | 50 | 50 | 50 |
Phase | 384 | 384 | 416 | 384 | 60 | 320 | 320 | 320 |
Acquisition time in min:s | 2:35 | 3:08 | 2:45 | 3:53 | 5:18 | 2:31 | 2:16 | 2:02 |
Table 2 Clinical and pathological characteristics of the patients’ studies
Characteristics | n (%) |
Sex | |
Female | 23 (48) |
Male | 25 (52) |
RECIST 1.1 | |
Partial response | 22 (46) |
Stable disease | 13 (27) |
Progressive disease | 13 (27) |
Ryan’s classification | |
0 | 18 (38) |
1 | 10 (21) |
2 | 9 (19) |
3 | 11 (22) |
Treatment response | |
Complete responders after nCRT | 18 (38) |
Non-responders’ patients after nCRT | 30 (62) |
Tumor location | |
Upper third | 7 (15) |
Middle third | 14 (29) |
Lower third | 20 (41) |
Diffuse | 7 (15) |
ypT stage | |
T0 | 4 (8) |
T1s | 4 (8) |
T1a | 2 (4) |
T2 | 8 (17) |
T3 | 20 (42) |
T4b | 10 (21) |
ypN stage | |
N0 | 20 (42) |
N1a | 14 (29) |
Nic | 14 (29) |
Degree of differentiation | |
Well-differentiated adenocarcinoma | 6 (13) |
Moderately differentiated adenocarcinoma | 35 (73) |
Poorly differentiated adenocarcinoma | 7 (14) |
Surgical approach | |
Low anterior resection | 16 (33) |
Intersphincteric resection | 26 (54) |
Abdominoperineal resection | 6 (13) |
Table 3 Median and interquartile range of pre- and post-neoadjuvant chemoradiation therapy parameters, as well as of changes between pre- and post-treatment values
Responders | Non-responders | P value | |
Pre-nCRT parameters | |||
pre-nCRT ADCmean | 0.75 (0.60-0.90) | 0.85 (0.70-0.90) | 0.146 |
10th percentile | 0.20 (0.17-0.23) | 0.20 (0.17-0.26) | 0.812 |
25th percentile | 0.32 (0.29-0.35) | 0.32 (0.23-0.41) | 1.000 |
50th percentile | 0.40 (0.35-0.40) | 0.40 (0.30-0.50) | 0.698 |
75th percentile | 0.56 (0.47-0.58) | 0.57 (0.45-0.63) | 0.391 |
90th percentile | 0.71 (0.55-0.77) | 0.76 (0.50-0.80) | 0.556 |
Skewness | 1.10 (0.90-1.14) | 1.19 (0.88-1.37) | 0.135 |
Kurtosis | 0.89 (0.83-0.92) | 0.92 (0.83-0.95) | 0.296 |
ROI ADCmean | 0.92 (0.80-1.20) | 0.91 (0.83-0.93) | 0.562 |
Post- nCRT parameters | |||
post- nCRT ADCmean | 1.20 (0.98-1.52) | 1.10 (0.90-1.30) | 0.065 |
10th percentile | 0.36 (0.30–0.37) | 0.32 (0.31–0.34) | 0.0361 |
25th percentile | 0.41 (0.40-0.52) | 0.42 (0.41-0.50) | 0.476 |
50th percentile | 0.66 (0.56-0.70) | 0.65 (0.51-0.66) | 0.127 |
75th percentile | 0.71 (0.67-0.80) | 0.70 (0.66-0.75) | 0.050 |
90th percentile | 0.89 (0.80-0.95) | 0.80 (0.79-0.89) | 0.105 |
Skewness | 0.92 (0.60–1.14) | 2.00 (1.15–2.67) | < 0.0011 |
Kurtosis | 0.65 (0.59–0.72) | 0.90 (0.80–0.90) | < 0.0011 |
ROI ADCmean | 2.50 (1.50-2.70) | 2.00 (1.80-2.30) | 0.056 |
Changes between pre-treatment and post-treatment | |||
∆%ADCmean | 57% (14%–103%) | 27% (0%–59%) | 0.0321 |
∆%ADC10th | 86% (37%–118%) | 48% (11%–88%) | 0.0201 |
∆%ADC25th | 39% (19%-57%) | 22% (0%-58%) | 0.905 |
∆%ADC50th | 70% (31%-86%) | 31% (2%-65%) | 0.067 |
∆%ADC75th | 40% (20%-61%) | 37% (0%-57%) | 0.288 |
∆%ADC90th | 27% (11%-58%) | 9% (7%-119%) | 0.061 |
∆skewness | –0.20 (–0.40–0.00) | 0.49 (0.10–0.50) | < 0.0011 |
∆%kurtosis | 41% (18%–54%) | 2.5% (1.4%–5.9%) | < 0.0011 |
ROI ∆%ADCmean | 55% (48%–60%) | 23% (15%–30%) | 0.0201 |
Table 4 Diagnostic performance of the best magnetic resonance imaging histogram derived parameters to detect responder patients
Cutoff | Sensitivity | Specificity | PPV | NPV | Accuracy | AUC (95%CI) | |
∆%kurtosis | 11.85% | 94.4% | 96.7% | 94.4% | 96.7% | 96.0% | 0.991 (0.925-1.000) |
Post-nCRT kurtosis | 0.78 | 93.3% | 99.0% | 90% | 99.0% | 96.0% | 0.985 (0.957-1.000) |
∆skewness | 0.16 | 66.7% | 99.0% | 64.3% | 99.0% | 79.2% | 0.885 (0.795-0.975) |
Post-nCRT skewness | 1.59 | 63.3% | 99.0% | 62.0% | 99.0% | 77.1% | 0.815 (0.795-0.634) |
Post-nCRT ADC10th | 0.34×10-3 mm2/s | 66.7% | 73.3% | 60.0% | 79.0% | 71.0% | 0.681 (0.509-0.852) |
∆%ADCmean | 56.00% | 56.0% | 77.0% | 56.0% | 73.3% | 66.7% | 0.686 (0.500-0.820 |
∆%ADC10th | 74.21% | 61.1% | 70.0% | 55.0% | 75.0% | 66.7% | 0.589 (0.483-0.815) |
ROI ∆%ADCmean | 55.00% | 61.0% | 69.0% | 52.0% | 72.0% | 65.3% | 0.583 (0.425-0.715) |
Table 5 Diagnostic odds ratios of magnetic resonance imaging parameters in differentiating respond and non- respond patients in locally advanced rectal cancer
Diagnostic odds ratio | 95%CI | |
∆%kurtosis | 376.0 | 228.9-842.1 |
Post-nCRT kurtosis | 375.3 | 225.7-887.7 |
∆skewness | 192.2 | 69.0-253.3 |
Post-nCRT skewness | 168.6 | 54.0-251.7 |
Post-nCRT ADC10th | 5.48 | 1.0-19.6 |
∆%ADCmean | 4.26 | 1.0-14.4 |
∆%ADC10th | 3.65 | 1.0-12.5 |
ROI ∆%ADCmean | 3.47 | 1.0-11.2 |
Table 6 Intraobserver variability
ICC | 95%CI | ||
Basal | |||
Test1 and test2, reader1 | ROI ADCmean | 0.850 | 0.742–0.800 |
Test1 and test2, reader2 | ROI ADCmean | 0.890 | 0.850-0.820 |
After treatment | |||
Test1 and test2, reader1 | ROI ADCmean | 0.800 | 0.750-0.819 |
Test1 and test2, reader2 | ROI ADCmean | 0.823 | 0.800-0.850 |
Basal | |||
Test1 and test2, reader1 | ADCmean | 0.850 | 0.756-0.920 |
Test1 and test2, reader2 | ADCmean | 0.777 | 0.745-0.812 |
After treatment | |||
Test1 and test2, reader1 | ADCmean | 0.845 | 0.830-0.850 |
Test1 and test2, reader2 | ADCmean | 0.823 | 0.800-0.833 |
Basal | |||
Test1 and test2, reader1 | 10th percentile | 0.820 | 0.880-0.950 |
Test1 and test2, reader2 | 10th percentile | 0.880 | 0.800-0.920 |
After treatment | |||
Test1 and test2, reader1 | 10th percentile | 0.780 | 0.740-0.853 |
Test1 and test2, reader2 | 10th percentile | 0.853 | 0.723-0.901 |
Basal | |||
Test1 and test2, reader1 | 25th percentile | 0.803 | 0.800-0.922 |
Test1 and test2, reader2 | 25th percentile | 0.863 | 0.801-0.895 |
After treatment | |||
Test1 and test2, reader1 | 25th percentile | 0.788 | 0.750-0.837 |
Test1 and test2, reader2 | 25th percentile | 0.820 | 0.780-0.846 |
Basal | |||
Test1 and test2, reader1 | 50th percentile | 0.850 | 0.840-0.920 |
Test1 and test2, reader2 | 50th percentile | 0.845 | 0.790-0.860 |
After treatment | |||
Test1 and test2, reader1 | 50th percentile | 0.821 | 0.800-0.913 |
Test1 and test2, reader2 | 50th percentile | 0.833 | 0.800-0.897 |
Basal | |||
Test1 and test2, reader1 | 75th percentile | 0.821 | 0.790-0.860 |
Test1 and test2, reader2 | 75th percentile | 0.859 | 0.820-0.920 |
After treatment | |||
Test1 and test2, reader1 | 75th percentile | 0.851 | 0.790-0.880 |
Test1 and test2, reader2 | 75th percentile | 0.837 | 0.791-0.856 |
Basal | |||
Test1 and test2, reader1 | 90th percentile | 0.850 | 0.820-0.890 |
Test1 and test2, reader2 | 90th percentile | 0.880 | 0.850-0.960 |
After treatment | |||
Test1 and test2, reader1 | 90th percentile | 0.831 | 0.800-0.902 |
Test1 and test2, reader2 | 90th percentile | 0.901 | 0.850-0.975 |
Basal | |||
Test1 and test2, reader1 | Skewness | 0.920 | 0.900-0.940 |
Test1 and test2, reader2 | Skewness | 0.901 | 0.880-0.923 |
After treatment | |||
Test1 and test2, reader1 | Skewness | 0.931 | 0.920-0.950 |
Test1 and test2, reader2 | Skewness | 0.889 | 0.877-0.910 |
Basal | |||
Test1 and test2, reader1 | Kurtosis | 0.920 | 0.890-0.950 |
Test1 and test2, reader2 | Kurtosis | 0.910 | 0.850-0.960 |
After treatment | |||
Test1 and test2, reader1 | Kurtosis | 0.890 | 0.850-0.960 |
Test1 and test2, reader2 | Kurtosis | 0.880 | 0.840-0.982 |
Table 7 Interobserver variability (intraclass correlation coefficient and 95% confidence intervals)
Pre-treatment | Reader one vs reader two | Post-treatment | Reader one vs reader two |
ROI ADCmean | 0.985 (1.900-0.999) | ROI ADCmean | 0.889 (0.850-0.950) |
ADCmean | 0.989 (0.980–0.994) | ADCmean | 0.990 (0.985-0.995) |
10th percentile | 0.972 (0.951–0.984) | 10th percentile | 0.992 (0.986–0.996) |
25th percentile | 0.970 (0.947–0.983) | 25th percentile | 0.950 (0.940-0.982) |
50th percentile | 0.986 (0.976–0.992) | 50th percentile | 0.987 (0.945-0.995) |
75th percentile | 0.989 (0.980–0.994) | 75th percentile | 0.990 (0.982–0.994) |
90th percentile | 0.989 (0.980–0.994) | 90th percentile | 0.972 (0.987–0.996) |
Skewness | 0.990 (0.982–0.994) | Skewness | 0.993 (0.987–0.996) |
Kurtosis | 0.992 (0.986–0.995) | Kurtosis | 0.972 (0.951–0.984) |
- Citation: Jiménez de los Santos ME, Reyes-Pérez JA, Domínguez Osorio V, Villaseñor-Navarro Y, Moreno-Astudillo L, Vela-Sarmiento I, Sollozo-Dupont I. Whole lesion histogram analysis of apparent diffusion coefficient predicts therapy response in locally advanced rectal cancer. World J Gastroenterol 2022; 28(23): 2609-2624
- URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2609.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i23.2609